Ana P. Vivancos

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 139 publications

Relative Mutant Allele Frequency Role in ctDNA-Guided Anti-Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer.

Relative Mutant Allele Frequency Role in ctDNA-Guided Anti-Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer.

Journal: JCO precision oncology

Published: September 01, 2026

Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.

Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.

Journal: JCO precision oncology

Published: September 01, 2026

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2-Amplified Metastatic Colorectal Cancer.

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2-Amplified Metastatic Colorectal Cancer.

Journal: JCO precision oncology

Published: July 29, 2026

Utility of archived EUS-guided fine-needle biopsy samples for next-generation sequencing in pancreatic adenocarcinoma.

Utility of archived EUS-guided fine-needle biopsy samples for next-generation sequencing in pancreatic adenocarcinoma.

Journal: Endoscopic ultrasound

Published: July 25, 2026

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Journal: Frontiers in oncology

Published: February 02, 2026

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 27, 2026

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Journal: NPJ precision oncology

Published: January 23, 2026

Homologous recombination deficiency testing implementation in the routine clinical setting: real-life experience and lessons learned.

Homologous recombination deficiency testing implementation in the routine clinical setting: real-life experience and lessons learned.

Journal: ESMO open

Published: January 22, 2026

Evolving landscape of targeted therapies in early phase clinical trials.

Evolving landscape of targeted therapies in early phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 04, 2026

Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.

Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.

Journal: ESMO open

Published: December 23, 2025

Immune checkpoint inhibition in Epstein-Barr virus associated gastric cancer: a case report highlighting the role of biomarker-driven treatment selection.

Immune checkpoint inhibition in Epstein-Barr virus associated gastric cancer: a case report highlighting the role of biomarker-driven treatment selection.

Journal: Frontiers in oncology

Published: December 20, 2025

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Journal: ESMO open

Published: December 17, 2025

Showing 1-12 of 139

Last Updated: 09/26/2026